Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-03-18 Purchase | 2024-03-20 5:22 pm | Ovid Therapeutics Inc. | OVID | LEVIN JEREMY M CEO | 18,248 | $2.76 | $50,364 | 3,652,176 (Indirect Direct) | View |
2022-09-12 Sale | 2022-09-14 4:58 pm | Ovid Therapeutics Inc. | OVID | Tardio Jason Chief Operating Officer | 17,344 | $2.15 | $37,290 | 0 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-09-09 Option Award | 2024-09-11 5:38 pm | N/A 2034-09-08 | Ovid Therapeutics Inc. | OVID | ALEXANDER MARGARET A. President and COO | 140,000 | $0 | 140,000 (Direct) | View |
Ownership | 2024-09-11 5:36 pm | N/A N/A | Ovid Therapeutics Inc. | OVID | ALEXANDER MARGARET A. President and COO | 0 | $0 | 868,896 (Direct) | View |
2024-07-30 Option Award | 2024-08-01 5:00 pm | N/A 2034-07-29 | Ovid Therapeutics Inc. | OVID | Rona Jeffrey A CBFO | 315,000 | $0 | 315,000 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 6:05 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Tardio Jason Chief Operating Officer | 196,875 | $0 | 196,875 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 6:03 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Rona Jeffrey A CBFO | 196,875 | $0 | 28,125 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 6:01 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Poole Robert Michael Director | 30,000 | $0 | 30,000 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 6:00 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Perone Thomas Michael General Counsel, Secretary | 196,875 | $0 | 196,875 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 5:58 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | LEVIN JEREMY M CEO | 700,000 | $0 | 700,000 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 5:57 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Friedman Bart Director | 30,000 | $0 | 30,000 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 5:56 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 30,000 | $0 | 30,000 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 5:54 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Duncan Barbara Gayle Director | 30,000 | $0 | 30,000 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 5:53 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Bernstein Karen Director | 30,000 | $0 | 30,000 (Direct) | View |
2023-12-04 Gift | 2023-12-06 5:05 pm | N/A N/A | Ovid Therapeutics Inc. | OVID | LEVIN JEREMY M CEO | 573,275 | $0 | 3,633,928 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 5:27 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Tardio Jason Chief Operating Officer | 175,000 | $0 | 175,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 5:24 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Rona Jeffrey A CBFO | 175,000 | $0 | 175,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 5:01 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Poole Robert Michael Director | 15,000 | $0 | 15,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 5:00 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Perone Thomas Michael General Counsel, Secretary | 175,000 | $0 | 175,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 4:58 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | LEVIN JEREMY M CEO 10% Owner | 600,000 | $0 | 600,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 4:55 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Friedman Bart Director | 15,000 | $0 | 15,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 4:51 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 15,000 | $0 | 15,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 4:47 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Duncan Barbara Gayle Director | 15,000 | $0 | 15,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 4:44 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Bernstein Karen Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-07-01 Other | 2022-07-06 06:28 am | N/A N/A | Ovid Therapeutics Inc. | OVID | TAKEDA PHARMACEUTICAL CO LTD Takeda Pharmaceuticals U.S.A. Inc. 10% Owner | 5,752,500 | $0 | 19,033,246 (Indirect) | View |
2022-04-08 Option Award | 2022-04-12 5:53 pm | N/A 2032-04-07 | Ovid Therapeutics Inc. | OVID | Friedman Bart Director | 69,424 | $0 | 69,424 (Direct) | View |
2022-04-08 Option Award | 2022-04-12 5:40 pm | N/A 2023-04-07 | Ovid Therapeutics Inc. | OVID | Tardio Jason Chief Operating Officer | 97,498 | $0 | 97,498 (Direct) | View |
2022-04-08 Option Award | 2022-04-12 5:36 pm | N/A 2032-04-07 | Ovid Therapeutics Inc. | OVID | LEVIN JEREMY M CEO 10% Owner | 423,244 | $0 | 423,244 (Direct) | View |
2022-04-08 Option Award | 2022-04-12 5:34 pm | N/A 2032-04-07 | Ovid Therapeutics Inc. | OVID | Rona Jeffrey A CBFO | 204,399 | $0 | 204,399 (Direct) | View |
2022-04-08 Option Award | 2022-04-12 5:30 pm | N/A 2032-04-07 | Ovid Therapeutics Inc. | OVID | Perone Thomas Michael General Counsel, Secretary | 35,399 | $0 | 35,399 (Direct) | View |
2022-04-08 Option Award | 2022-04-12 4:55 pm | N/A 2032-04-07 | Ovid Therapeutics Inc. | OVID | Duncan Barbara Gayle Director | 21,347 | $0 | 21,347 (Direct) | View |
2022-04-08 Option Award | 2022-04-12 4:44 pm | N/A 2032-04-07 | Ovid Therapeutics Inc. | OVID | Bernstein Karen Director | 69,424 | $0 | 69,424 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 8:51 pm | N/A 2032-02-03 | Ovid Therapeutics Inc. | OVID | Poole Robert Michael Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 8:50 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Friedman Bart Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 8:49 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 8:48 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Duncan Barbara Gayle Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 8:47 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Bernstein Karen Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 6:24 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Tardio Jason Chief Operating Officer | 175,000 | $0 | 175,000 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 6:22 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Rona Jeffrey A CBFO | 218,750 | $0 | 218,750 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 6:19 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Perone Thomas Michael General Counsel, Secretary | 175,000 | $0 | 175,000 (Direct) | View |